Page last updated: 2024-12-08
tyrosinyl-5'-amp
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
tyrosinyl-5'-AMP: RN given refers to S-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 169008 |
MeSH ID | M0072142 |
Synonyms (9)
Synonym |
---|
adenylyl-tyrosine |
TYA , |
6372-08-3 |
[(2s)-2-amino-3-(4-hydroxyphenyl)propyl] [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate |
tyrosyl adenylate |
(s)-5'-adenylic acid, mono(2-amino-3-(4-hydroxyphenyl)propyl) ester |
tyrosinyl-5'-amp |
9-(5-o-{[2-amino-3-(4-hydroxyphenyl)propoxy](hydroxy)phosphoryl}pentofuranosyl)-9h-purin-6-amine |
DTXSID70980163 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (50.00) | 18.7374 |
1990's | 2 (12.50) | 18.2507 |
2000's | 4 (25.00) | 29.6817 |
2010's | 2 (12.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.59) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |